Everest Organics Ltd.

Financial

	Everest Organics	SMS Lifesciences	Nectar Lifesciences
Operational Metrics
API Sector
Manufacturing Capacity - Esomeprazole	144.0 MTPA	n/a	n/a
Capacity Utilization - Esomeprazole	65.56 %	n/a	n/a
Capacity Utilization - Benzimidazole	87.52 %	n/a	n/a
Capacity Utilization - Omeprazole	85.77 %	n/a	n/a
Realization - Pantaprazole Sodium	4015482.23 Rs/Tonne	n/a	n/a
Realization - Ammonium Sulphate	22104.75 Rs/Tonne	n/a	n/a
Realization - Esomeprazole Magnesium	3625281.87 Rs/Tonne	n/a	n/a
Realization - Chloro Compound	2039819.1 Rs/Tonne	n/a	n/a
Manufacturing Capacity - Pantaprazole	60.0 MTPA	n/a	n/a
Realization - Omeprazole Powder	2963407.74 Rs/Tonne	n/a	n/a
Manufacturing Capacity - Benzimidazole	250.0 MTPA	n/a	n/a
Capacity Utilization - Chloro Compound	70.95 %	n/a	n/a
Realization - Benzimidazole	1270727.38 Rs/Tonne	n/a	n/a
Realization - Op. Sulphide	2949666.67 Rs/Tonne	n/a	n/a
Capacity Utilization - Pantaprazole	13.43 %	n/a	n/a
Manufacturing Capacity - Chloro Compound	480.0 MTPA	n/a	n/a
Realization - Tetralone	700000.0 Rs/Tonne	n/a	n/a
Manufacturing Capacity - Omeprazole	215.0 MTPA	n/a	n/a
Pharmaceutical Sector
R&D as a % of Total Sales	1.13 %	n/a	0.85 %
Financials
5 yr Average ROE	12.73 %	9.57 %	-0.71 %
5yr average Equity Multiplier	3.91	2.31	2.17
5yr Average Asset Turnover Ratio	1.13	0.88	0.74
5yr Avg Net Profit Margin	2.92 %	4.57 %	-0.63 %
Price to Book	9.26	2.15	0.46
P/E	0.0	17.5	29.31
5yr Avg Cash Conversion Cycle	-87.83 Days	-0.85 Days	81.28 Days
Inventory Days	61.25 Days	83.06 Days	136.26 Days
Days Receivable	142.15 Days	52.44 Days	62.43 Days
Days Payable	226.8 Days	150.03 Days	113.03 Days
5yr Average Interest Coverage Ratio	3.02	4.15	0.94
5yr Avg ROCE	19.01 %	10.58 %	7.51 %
5yr Avg Operating Profit Margin	6.68 %	10.06 %	7.57 %
5 yr average Debt to Equity	0.84	0.54	0.73
5yr CAGR Net Profit	-58.15 %	-2.24 %	-31.15 %
5yr Average Return on Assets	3.96 %	4.11 %	-0.34 %
Shareholdings
Promoter Holding	61.09 %	71.41 %	44.53 %
Share Pledged by Promoters	0.0	0.0	99.6 %
Change in Promoter Holding (3 Yrs)	-13.06 %	2.45 %	-11.27 %
Change in Mutual Fund Holding (3 Yrs)	0.0	0.0	0.0

Business

	Everest Organics	SMS Lifesciences	Nectar Lifesciences
Product Wise Break-Up	Product Wise Break-Up Omeprazole Powder 46.36 Esomeprazole Magnesium 38.94 Pantaprazole Sodium 5.59 Rabeprazole 5.3 Fenofibrate 3.38 Dexlansoprazole 0.43 Oseltamivir 0 Tetralone 0 Ammonium Sulphate 0 Op. Sulphide 0 Chloro Compound 0 Benzimidazole 0 API`S 0 Drugs and Pharmaceuticals 0	Product Wise Break-Up Tetralone 0 Benzimidazole 0 Fenofibrate 0 Dexlansoprazole 0 API`S 0 Esomeprazole Magnesium 0 Oseltamivir 0 Op. Sulphide 0 Ammonium Sulphate 0 Pantaprazole Sodium 0 Chloro Compound 0 Rabeprazole 0 Omeprazole Powder 0 Drugs and Pharmaceuticals 0 Others 100	Product Wise Break-Up Tetralone 0 Benzimidazole 0 Fenofibrate 0 Dexlansoprazole 0 API`S 0 Esomeprazole Magnesium 0 Oseltamivir 0 Op. Sulphide 0 Ammonium Sulphate 0 Pantaprazole Sodium 0 Chloro Compound 0 Rabeprazole 0 Omeprazole Powder 0 Pharmaceuticals 100.0
Segment Break-Up	Segment Break-Up Active Pharmaceutical Ingredient (API) 100.0	-	-
Location Wise Break-Up	Location Wise Break-Up India 73.7 Rest of the World 26.3	Location Wise Break-Up Rest of the World 44.33 India 55.66 Others 0.01	Location Wise Break-Up Rest of the World 40.47 India 59.53
Raw Material Break-Up	Raw Material Break-Up 3, 5 Lutidine 40.3 Para Anisidine 13.59 Toluene 12.23 Acetone 11.13 MDC 786.60 7.9 APS 206.88 6.87 Acetic Acid 4.77 DMS 299.44 3.21 Others 0	-	-

Everest Organics Ltd.

SIGN UP FOR FREE